Biometric company VAXSYS Technologies Inc on Wednesday announced the availability of the fast, simple, accurate and secure Barcodes Inc/VAXSYS COVID-19 Vaccination Enrollment and Verification System to provide a durable record of COVID-19 vaccinations as required.
The enrollment component of the Barcodes Inc/VAXSYS System is mobile, accurate and paper free that provides the ability to print and issue durable, legible vaccine credentials on secure plastic VAXSYS Cards that contain an encrypted, fraud-resistant 2D barcode.
In addition, the verification component of the Barcodes Inc/VAXSYS System is a mobile App which can be downloaded on to any Android handheld device with 2D barcode reading capability. The App decrypts the barcode on the VAXSYS Card to generate an anonymous, immediate, level-1 proof of COVID-19 vaccination, without requiring any additional personal, biographic or biometric information.
With provision for all the necessary hardware and software, the Barcodes Inc/VAXSYS System can be operated in stand-alone mode, or integrated into a user database at the option of the user. The card can be printed with the name of the business, university or sports team.
Headquartered in Chicago, IL, Barcodes Inc is an information technology solution company with more than a 26-year history of providing products, software and services to automate businesses.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine